Net debt increased to $596.8 million due to share repurchases and acquisition payments; leverage ratio was 2.5x adjusted EBITDA.
Net income was $19.4 million or $1.09 per diluted share, down from $37.5 million or $2.03 per diluted share in Q2 2024, impacted by an $8.2 million noncash impairment charge.
Operating income margins improved in Healthcare (30.2% vs 29.1%) and Commercial (16.6% vs 15.3%), Education margin stable at 25%.
Operating income margins improved in Healthcare (30.2% vs 29.1%) and Commercial (16.6% vs 15.3%), stable in Education (25% vs 25.1%).
Revenues before reimbursable expenses (RBR) grew 8% over Q2 2024, reaching a record high.